Background: COVID-19 has been ravaging the globe for more than three years. Due to systemic immunosuppression of anti-tumor therapy, application of chemotherapy and adverse effects of surgery, the short- and long-term prognosis of cancer patients to COVID-19 are of significant concern.Method: This research included three parts of data. The first part of the data came from the public database that covered Veneto residents. The second part of the data included participants in Guangzhou. The third part of the data was used for MR analysis. We assessed the associations by logistic, linear or Cox regression when appropriate.Result: Lung cancer patients with COVID-19 had shorter progression-free survival (PFS) after COVID-19 (Model II: HR: 3.28, 95% CI: 1.6~6.72; Model III: HR: 3.39, 95% CI: 1.45~7.95), compared with lung cancer patients without COVID-19. Targeted therapy patients recovered from SARS-CoV-2 infection more quickly (Model I: β: −0.58, 95% CI: −0.75~−0.41; Model II: β: −0.59, 95% CI: −0.76~−0.41; Model III: β: −0.57; 95% CI: −0.75~−0.40).Conclusions: PFS in lung cancer patients is shortened by COVID-19. The outcome of COVID-19 in lung cancer patients was not significantly different from that of the healthy population. In lung cancer patients, targeted therapy patients had a better outcome of COVID-19, while chemotherapy patients had the worst.
背景：新型冠状病毒肺炎（COVID-19）已在全球肆虐三年有余。由于抗肿瘤治疗导致的系统性免疫抑制、化疗药物的应用以及手术的不良影响，癌症患者感染COVID-19后的短期与长期预后备受关注。 方法：本研究包含三部分数据。第一部分数据来源于覆盖威尼托地区居民的公共数据库；第二部分数据纳入广州地区的参与者；第三部分数据用于孟德尔随机化分析。我们根据数据类型适用逻辑回归、线性回归或Cox回归模型进行关联性评估。 结果：与未感染COVID-19的肺癌患者相比，感染COVID-19的肺癌患者在感染后无进展生存期显著缩短（模型II：HR=3.28，95% CI：1.6~6.72；模型III：HR=3.39，95% CI：1.45~7.95）。接受靶向治疗的患者从SARS-CoV-2感染中恢复更快（模型I：β=-0.58，95% CI：-0.75~-0.41；模型II：β=-0.59，95% CI：-0.76~-0.41；模型III：β=-0.57，95% CI：-0.75~-0.40）。 结论：COVID-19会缩短肺癌患者的无进展生存期。肺癌患者感染COVID-19的临床结局与健康人群无显著差异。在肺癌患者中，接受靶向治疗者COVID-19预后最佳，而接受化疗者预后最差。
Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions
肿瘤(癌症)患者之家